S019 Nail Symposium
DESCRIPTION
This session provides the most comprehensive up-to-date information on diagnosis and treatment of major nail disorders. Recognized experts from around the world will discuss the most current scientific evidence regarding onychomycosis, nail unit psoriasis, nail unit lichen planus, trachyonychia, nail unit melanoma, nail disorders in skin of color patients, onycholysis, paronychia, as well as others. Instructive nail cases are also included. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Select the optimal biologic medications for patients with nail psoriasis.
Describe how to evaluate and manage patients with onychomycosis and terbinafine resistance.
Describe the most up to date information on the diagnosis and treatment of nail unit melanoma.
SCHEDULE
1:00 PM
Evaluation and management of onychomycosis in the face of emerging terbinafine resistance
Aditya K. Gupta, MD, PhD, FAAD
1:10 PM
Trachyonychia diagnosis and therapy
Avner Shemer, MD, IFAAD
1:20 PM
Nail disorders in skin of color patients
Antonella Tosti, MD
1:30 PM
Nail psoriasis: which biologic should I choose?
Dimitris Rigopoulos, MD, IFAAD
1:40 PM
Primer on nail CPT coding and Medicare payment updates
Julia O'Brien Baltz, MD, FAAD
1:50 PM
Questions and Answers
2:00 PM
Advances in the diagnosis and treatment of nail unit melanoma
Shari Lipner, MD, PhD, FAAD
2:10 PM
Updates on the diagnosis and management of benign nail tumors
Matilde Iorizzo, PhD, MD, IFAAD
2:20 PM
Treating Nail Surgery Complications
Bertrand Richert, MD, PhD, IFAAD
2:30 PM
Maximizing patient satisfaction for onycholysis and paronychia
C. Ralph Daniel, MD, FAAD
2:40 PM
State of the art patient evaluation and treatment of nail unit squamous cell carcinoma
Nathaniel J. Jellinek, MD, FAAD
2:50 PM
Questions and Answers
3:00 PM
My instructive nail case: Dr. April Schachtel
April Schachtel, MD, FAAD
3:05 PM
My instructive nail case: Dr. Kimberly Ken
Kimberly Marie Ken, MD, FAAD
3:10 PM
My instructive nail case: Dr. Phoebe Rich
Phoebe Rich, MD, FAAD
3:15 PM
My instructive nail case: Dr. Dongyoun Lee
Dong-Youn Lee, MD, PhD, IFAAD
3:20 PM
My instructive nail case: Dr. Beth Ruben
Beth S. Ruben, MD, FAAD
3:25 PM
My instructive nail case: Dr. Julie Mervak
Julie Mervak, MD, FAAD
3:30 PM
My instructive nail case: Dr. Jane Bellet
Jane S. Bellet, MD, FAAD
3:35 PM
My instructive nail case: Dr. Marty Zaiac
Martin N. Zaiac, MD, FAAD
3:40 PM
My instructive nail case: Dr. Mark Holzberg
Mark J. Holzberg, MD, FAAD
3:45 PM
My instructive nail case: Dr. Christoph Loser
Christoph R. Loeser, MD, IFAAD
3:50 PM
Questions and Answers
DIRECTOR
Adam Rubin, MD, FAAD
SPEAKERS
Julia O'Brien Baltz, MD, FAAD
Jane S. Bellet, MD, FAAD
C. Ralph Daniel, MD, FAAD
Aditya K. Gupta, MD, PhD, FAAD
Mark J. Holzberg, MD, FAAD
Matilde Iorizzo, PhD, MD, IFAAD
Nathaniel J. Jellinek, MD, FAAD
Kimberly Marie Ken, MD, FAAD
Dong-Youn Lee, MD, PhD, IFAAD
Shari Lipner, MD, PhD, FAAD
Christoph R. Loeser, MD, IFAAD
Julie Mervak, MD, FAAD
Phoebe Rich, MD, FAAD
Bertrand Richert, MD, PhD, IFAAD
Dimitris Rigopoulos, MD, IFAAD
Beth S. Ruben, MD, FAAD
April Schachtel, MD, FAAD
Avner Shemer, MD, IFAAD
Antonella Tosti, MD
Martin N. Zaiac, MD, FAAD
HANDOUTS
DISCLOSURES
Julia O'Brien Baltz, MD, FAAD
No financial relationships exist with ineligible companies.
Jane S. Bellet, MD, FAAD
Maui Derm – Speaker(Honoraria); Merck & Co., Inc. – Stockholder(No Compensation Received); NobelPharma – Consultant (1099 relationship)(Honoraria);
C. Ralph Daniel, MD, FAAD
Elsevier Inc. – Other(Patent royalties or other compensation for Intellectual Property Rights); Medimetriks Pharmaceuticals, Inc. – Advisory Board(Stock Options); Ortho Dermatologics – Advisory Board(Honoraria); Springer Science & Business Media – Other(Fees); Visiting Professor – Speaker(Honoraria);
Aditya K. Gupta, MD, PhD, FAAD
Bausch Health – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Emblation Limited – Investigator(Grants/Research Funding); Moberg Derma – Consultant(Fees); Ortho Dermatologics – Consultant(Fees);
Mark J. Holzberg, MD, FAAD
Wiley-Blackwell – Other(Patent royalties or other compensation for Intellectual Property Rights);
Matilde Iorizzo, PhD, MD, IFAAD
No financial relationships exist with ineligible companies.
Nathaniel J. Jellinek, MD, FAAD
No financial relationships exist with ineligible companies.
Kimberly Marie Ken, MD, FAAD
No financial relationships exist with ineligible companies.
Dong-Youn Lee, MD, PhD, IFAAD
No financial relationships exist with ineligible companies.
Shari Lipner, MD, PhD, FAAD
BelleTorus Corporation – Investigator(Grants/Research Funding); Moberg Pharma North America LLC – Investigator(Grants/Research Funding);
Christoph R. Loeser, MD, IFAAD
No financial relationships exist with ineligible companies.
Julie Mervak, MD, FAAD
No financial relationships exist with ineligible companies.
Phoebe Rich, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Alfasigma Global – Investigator(Grants/Research Funding); Allakos – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Investigator(Grants/Research Funding); ASLAN Pharmaceuticals – Investigator(Grants/Research Funding); Atacama Therapeutics – Investigator(Grants/Research Funding); Brickell Biotech, Inc – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Cara Therapeutics – Advisory Board(Honoraria); Dermavant Sciences – Investigator(Grants/Research Funding); DermBiont – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); Galderma Laboratories, L.P. – Investigator(Grants/Research Funding); Hallux, Inc. – Investigator(Grants/Research Funding); Incyte – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Janssen-Ortho Inc. – Investigator(Grants/Research Funding); La Roche Posay Dermatologique – Advisory Board(Honoraria); Leo Pharma Inc – Investigator(Grants/Research Funding); Moberg Derma – Investigator(Grants/Research Funding); Ortho Dermatologics – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); UCB – Investigator(Grants/Research Funding);
Bertrand Richert, MD, PhD, IFAAD
No financial relationships exist with ineligible companies.
Dimitris Rigopoulos, MD, IFAAD
No financial relationships exist with ineligible companies.
Beth S. Ruben, MD, FAAD
No financial relationships exist with ineligible companies.
Adam Rubin, MD, FAAD
Lippincott Wiliams & Wilkins – Other(Other Financial Benefit); New York University Langone Medical Center – Employee – Lab does not sell products(Salary); Springer Publishing – Other(Other Financial Benefit);
April Schachtel, MD, FAAD
No financial relationships exist with ineligible companies.
Avner Shemer, MD, IFAAD
AbbVie – Speaker/Faculty Education(Fees); AMI Technologies – Consultant(Fees); Eli Lilly and Company – Speaker/Faculty Education(Fees); Ex-It Medical Devices Limited – Consultant(Fees); GlaxoSmithKline – Speaker/Faculty Education(Fees); Janssen Biotech – Speaker/Faculty Education(Fees); NeoPharm Israel – Consultant(Fees); Novartis – Speaker/Faculty Education(Fees); Perrigo Company – Speaker/Faculty Education(Fees); Pfizer Inc. – Speaker/Faculty Education(Fees); Sanofi – Speaker/Faculty Education(Equipment);
Antonella Tosti, MD
Almirall – Advisory Board(Fees); Bristol-Myers Squibb – Advisory Board(Fees); Concert Pharmaceuticals – Investigator(Salary); DS Laboratories – Consultant(Fees); Eli Lilly and Company – Consultant(Honoraria), Investigator(Salary); Myovant Sciences – Advisory Board(Fees); Ortho Dermatologics – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Honoraria); Springer Science & Business Media – Other(Patent royalties or other compensation for Intellectual Property Rights); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); Taylor & Francis – Other(Patent royalties or other compensation for Intellectual Property Rights); Thirty Madison, Inc. – Consultant(Honoraria);
Martin N. Zaiac, MD, FAAD
No financial relationships exist with ineligible companies.